Suzuki, Kenshi
Doki, Noriko
Meguro, Kuniaki
Sunami, Kazutaka
Kosugi, Hiroshi
Sasaki, Osamu
Takagi, Toshiyuki
Murakami, Hirokazu
Shimizu, Kazuyuki
Funding for this research was provided by:
Fujimoto Pharmaceutical Corporation
Article History
Received: 15 January 2019
Revised: 26 June 2019
Accepted: 26 June 2019
First Online: 19 July 2019
Compliance with ethical standards
:
: K Suzuki served on scientific advisory boards and speakers’ bureaus for Takeda Pharmaceutical Co. Ltd., Bristol-Myers Squibb K. K., and received honoraria from Janssen Pharmaceutical K. K., Novartis Pharma K. K., Celgene K. K., Fujimoto Pharmaceutical Corp., and Takeda Pharmaceutical Co. Ltd. K. Sunami received research grants from Fujimoto Pharmaceutical Corp., Novartis Pharma K. K., GlaxoSmithKline K. K. Janssen Pharmaceutical K. K., Abbvie GK., Takeda Pharmaceutical Co. Ltd., Sanofi K. K., Bristol-Myers Squibb K. K., Ono Pharmaceutical Co. Ltd., MSD K. K., Alexion Pharma, Daiichi-Sankyo Co. Ltd., Celgene K. K., and honoraria from Takeda Pharmaceutical Co. Ltd., Bristol-Myers Squibb K. K., Ono Pharmaceutical Co. Ltd., Celgene K. K.Y. T. Takagi received consulting fees from Fujimoto Pharmaceutical Corp. H. Murakami received a research grant from Fujimoto Pharmaceutical Corp. and Celgene K. K., and served on scientific advisory boards and speakers’ bureaus for Celgene K. K., Sanofi K. K. and Ono Pharmaceutical Co. Ltd. K. Shimizu received consulting fees from Daiichi-Sankyo Co. Ltd. and Fujimoto Pharmaceutical Corp. N. Doki, K. Meguro, H. Kosugi and O. Sasaki declare no conflict of interest.